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Background: The past decade has seen the emergence of several molecular tools that render possible
modification of cellular functions through accurate and easy addition, removal, or exchange of genomic DNA
sequences. Among these technologies, transcription activator-like effectors (TALE) has turned out to be one of the
most versatile and incredibly robust platform for generating targeted molecular tools as demonstrated by fusion to
various domains such as transcription activator, repressor and nucleases.
Results: In this study, we generated a novel nuclease architecture based on the transcription activator-like effector
scaffold. In contrast to the existing Tail to Tail (TtT) and head to Head (HtH) nuclease architectures based on the
symmetrical association of two TALE DNA binding domains fused to the C-terminal (TtT) or N-terminal (HtH) end of
FokI, this novel architecture consists of the asymmetrical association of two different engineered TALE DNA binding
domains fused to the N- and C-terminal ends of FokI (TALE::FokI and FokI::TALE scaffolds respectively). The
characterization of this novel Tail to Head (TtH) architecture in yeast enabled us to demonstrate its nuclease activity
and define its optimal target configuration. We further showed that this architecture was able to promote substantial
level of targeted mutagenesis at three endogenous loci present in two different mammalian cell lines.
Conclusion: Our results demonstrated that this novel functional TtH architecture which requires binding to only one
DNA strand of a given endogenous locus has the potential to extend the targeting possibility of FokI-based
TALE nucleases.
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Transcription activator-like effectors (TALEs), a group of
bacterial plant pathogen proteins, have recently emerged
as new engineerable scaffold for production of engineered
DNA binding domains with chosen specificities [reviewed
in [1]]. The targeting specificity of this family of proteins is
driven by a central core composed of multiple repeated
units. These 33 to 35 amino acids repeated units are nearly
identical to one another except for two polymorphic amino
acids called RVDs (repeat variable di residue), responsible
for the specific recognition of a unique nucleotide [2,3]. In* Correspondence: alexandre.juillerat@cellectis.com;
philippe.duchateau@cellectis.com
†Equal contributors
CELLECTIS S.A, 8 Rue de la Croix Jarry, Paris 75013, France
© 2014 Juillerat et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.addition to this central core domain, the N-terminal do-
main of TALE has been reported to play a key role in
TALEs specificity and binding mechanism. This domain
displays a strong specificity bias toward a thymine nucleo-
tide, the so called “T0”, systematically located at the 5’end
of the TALE target [2]. These different biochemical features
were confirmed by the high resolution structure of TALE/
DNA complexes, illustrating how the TALE protein wraps
around its DNA target, from the 5’ T0 to the 3’ last nucleo-
tide, in an N- to C-terminal orientation [4-6]. The par-
ticular DNA binding properties of TALE DNA binding
domain, their exquisite specificity as well as their modular-
ity have been used to develop engineered TALE nucleases
named TALEN with tailored DNA specificity. The original
TALEN architecture developed by Christian et al. [7],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to the N-terminal end of the non-specific FokI nuclease
domain (TALE::FokI scaffold, Figure 1A). Because FokI
needs to dimerize to catalyze a double strand break (DSB),
TALEN work by pairs. Each pair unit binds in a Tail to
Tail (TtT) orientation to adjacent binding sites, start-
ing by a 5’ T0 and respectively located on the sense
and antisense strand of the DNA. Such symmetricalFigure 1 Design, creation and In vivo characterization of the three nu
(A) Schematic representation of the two different scaffolds used in this stu
domain as well as the Tail and Head positions. (B) Schematic representatio
The reporter plasmid containing a Nuclease Target Sequence (NTS) is flank
target sequence in yeast leads to the restoration of the LacZ marker throug
restoration of the functional LacZ gene is quantified by a β-galactosidase activi
examples of activity measurements from the yeast SSA assay for the three arch
TALE scaffolds are facing each other on the two DNA strands and in a head to
scaffolds are facing each other on the two DNA strands and in a Tail to
TALE scaffolds are facing each other on the same DNA strand and in a T
architectures in yeast using the single strand annealing assay (SSA) as a
of each figure panels. For each filter, three controls (negative control, wea
Standard deviation on these activity measurements were typically of 0.05.architecture, originally designed to respect (i), the nat-
ural organization of the endonuclease and DNA bind-
ing domains of FokI (ii), the orientation of TALE DNA
binding and (iii), the requirement of a T0, led to an in-
credibly robust TALE-based nuclease platform. Con-
sidered as the gold standard TALEN architecture, it has
been extensively optimized and used for different gene
editing applications [8,9]. Furthermore, the versatility ofclease architectures based on the FokI catalytic domain in yeast.
dy including the positions of N and C-terminal domains, DNA binding
n of the yeast extrachromosomal single strand annealing (SSA) assay.
ed by overlapping truncated LacZ genes sequences. Cleavage of the
h the single strand annealing (SSA) pathway of recombination. The
ty assay and related to the nuclease efficiency. (C, D and E) Representative
itectures obtained on the same filter. (C) HtH architecture where two FokI::
head orientation. (D) Classical TtT architecture where two TALE::FokI
Tail orientation. (E) TtH architecture where a TALE::FokI and a FokI::
ail to Head orientation. The nuclease activity measured for the three
function of target spacer length (5-35 bp) is displayed at the bottom
k nuclease and strong nuclease) were measured multiple times (n > 100).
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studies reporting fusion (N-terminal as well as C-terminal)
of the TALE core to various catalytic domains [10-21]. In
particular, we [22] and others [23] have reported the devel-
opment of TALE-based nuclease with an N-terminal fusion
FokI catalytic domain.
In this study, we further explored and exploited the
versatility of the TALE scaffold to develop a novel asym-
metrical hybrid TALE and FokI-based nuclease architec-
tures, the Tail to Head (TtH) architecture referred herein
as TtH. We demonstrated the potential of this architec-
ture to generate targeted mutagenesis at different en-
dogenous loci in mammalian cells. In contrast to the
conventional TALEN architecture, the TtH architecture
only required one DNA strand of a given locus to effi-
ciently bind and process it. Thus, our work presents a new
advance in the development of TALE nucleases and fur-
ther extends their targeting possibilities.
Results
Design and evaluation of the Head to Head (HtH)
symmetrical architecture in a yeast SSA assay
To investigate the versatility of the TALE scaffold and
generate alternative nuclease architectures, we used a
yeast-based nuclease activity assay [24]. This assay was
previously demonstrated to be suitable to assess the in-
trinsic nuclease activity of TALE nuclease without being
biased by epigenetic modifications or chromatin context.
In addition, we have previously found a good correlation
between data obtained with the yeast SSA assay, an
extrachromosomal SSA assay in CHO-K1 and chromo-
somal disruption experiments in CHO-KI [25,26]. We
thus believed that the yeast model system could serve as
an appropriate and representative assay to compare
characteristics of different nuclease architectures. This
assay relies on two yeast strains, one expressing the nu-
clease of interest and the other the target sequence
flanked by overlapping truncated LacZ genes (Figure 1B).
After mating of the two strains, the restoration, upon
target cleavage, of the LacZ marker though the SSA
pathway of recombination recontitute a functional LacZ
gene. The resulting β-galactosidase can further be quan-
tified and related to the nuclease efficiency. The experi-
mental conditions were optimized to avoid saturation of
the signal, thus allowing a direct comparison on the
whole range of activities.
In order to evaluate alternative configurations to the
standard TtT TALEN (symmetrical association of two
TALE::FokI scaffolds, Figure 1A), we designed a con-
struction harboring a FokI catalytic domain fused to the
N-terminal domain of a TALE (FokI::TALE scaffold),
leading to the symmetrical head-to-head nuclease archi-
tecture referred herein as HtH (Figure 1C). Throughout
this study we used the avirulence protein AvrBs3 asscaffold (accession number P14727). The first step for
developing the alternative HtH and TtH architectures
was to re-engineer a fusion protein to create an efficient
FokI::TALE scaffold. Early works performed on TALE
protein showed that the first 152 amino acids of the
N-terminal domain could be deleted (Δ152 variant)
without affecting the protein activity [27]. We used an
approach previously described to create an active I-
TevI based TALE nuclease [22] and fused the FokI
catalytic domain (amino acids 388 to 583, accession
number P14870) to the N-terminal end of the Δ152
TALE variant via a 4 aminoacids (-GSSG-) flexible
linker. In addition, we removed most of the C-terminal
end of the TALE domain (keeping only the first 11 amino
acids, amino acids 887 to 897, accession number P14727)
to minimize the global size of the final protein. To allow
the specific targeting of the desired DNA sequences, we
used the canonical RVD/nucleotide association code (NI:
A, HD:C, NN:G and NG:T) [2,3].
A RVD array targeting an 18 base pairs sequence of
interest (ATATAAACCTAACCCTCT, Additional file 1:
Table S2) was cloned into the FokI::TALE backbone.
The nuclease activity of the resulting construction was
tested in yeast using the extrachromosomal single strand
annealing (SSA) assay (Figure 1B) and homodimeric
DNA targets containing respectively two identical recog-
nition sequences juxtaposed with the 5’ ends proximal
(Figure 1C). To determine the optimal distance for
cleavage activity between the two recognition domains, a
series of homodimeric targets were designed with spacers
ranging from 5 to 35 bp (Figure 1C, Additional file 1:
Table S2). Furthermore, we also prepared the classical
TtT TALEN targeting the same DNA sequence to
serve as a reference for the currently used architecture
(Figure 1D). In this study, we used a + C40 (amino
acids 887 to 926, accession number P14727, followed
by a 4 aminoacids –ISRS- linker) TALEN scaffold as,
in our hands, this truncation presented a good balance
to obtain a high activity associated with a good specifi-
city (narrow spacer window). We additionally designed
series of homodimeric targets containing respectively
two identical recognition sequences juxtaposed with
the 3’ ends proximal (Figure 1D, Additional file 1:
Table S3) with the same spacing described above. The
results obtained from this SSA assay showed that, des-
pite not preserving the natural N-terminus (DNA binding
domain) to C-terminus (catalytic domain) layout of the
wild-type FokI, similar levels of activity for both architec-
tures can be obtained (Figure 1C and 1D). Interestingly, one
major difference between the two configurations was the
spacing pattern reached by the HtH architecture, with a
much narrower window of cleaved spacers compared to the
ones obtained for the classical architecture (22 to 27 bp for
the HtH nuclease versus 10 to 27 bp for the TtT nuclease).
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asymmetrical architecture in a yeast SSA assay
Having demonstrated that the FokI::TALE scaffold dis-
play a high nuclease activity in a symmetrical HtH con-
figuration, we next evaluated its ability to pair up with
the TALE::FokI fusion scaffold and produce an active
nuclease (Additional file 1: Figure S1E). The nuclease ac-
tivity of the resulting asymmetric tail-to-head architec-
ture, referred herein as TtH, was assessed in yeast on a
collection of hybrid asymmetric targets. These targets
contained two different recognition sequences juxta-
posed with the 3′-5′ ends proximal and separated by
a DNA spacer ranging from 5 to 35 bp (Figure 1E,
Additional file 1: Table S4). The yeast SSA assay results
showed activity levels comparable to the ones observed
for TtT and HtH architectures, with two distinct windows
of cleaved DNA spacers (18 to 22 bp and 27 to 33 bp;
Figure 1E). This result suggested an optimal cleavage
every one helix turn of DNA. Interestingly, the optimal
cleavage distance of TtH architecture was 5 bp shorter
than the one obtained for HtH architecture (20 and
25 bp respectively).
Nuclease activities of TtH asymmetrical architecture in
mammalian cells and molecular characterization of
nuclease-induced events
Once the activity of the new TtH architecture was demon-
strated in yeast, we next investigated its activity in mamma-
lian cells. Two loci of interest for potential therapeutic
applications, previously chosen to investigate other tailored-
made nucleases [25], DMD (gene involved in the Duchenne
Muscular Dystrophies) and RAG1 (V(D)J recombination-
activating protein 1), were selected in the human genome
and an additional locus of interest for bioproduction, the
fucosyltransferase 8 (FUT8) gene, was chosen in the Chinese
hamster genome.
Because the nuclease activity of HtH architecture to-
wards endogenous loci had never been reported, we also
characterized this architecture in the following experi-
ments. Targets were selected for both nuclease architec-
tures according to the spacer profile (25 bp and 20 bp
for HtH and TtH respectively) determined previously with
the yeast SSA assay (Figure 1C and 1E). The nucleases
were then assembled using the optimal scaffolds contain-
ing an additional N-terminal SV40 nuclear localization
sequence to improve their in vivo nuclear targeting
(Additional file 1: Table S5). These nucleases were then
assayed for their ability to promote targeted insertions
or deletions of nucleotides (indels) via error prone non-
homologous end joining (NHEJ, Figure 2A), in the ad-
equate cell-line (293H or CHO-KI, Table 1).
Three days post transfection, genomic DNAs were re-
covered and amplified by locus specific PCRs (370 to
630 bp). PCR amplicons were then analyzed by deepsequencing to determine the amount of Indels promoted
by the different nucleases at their respective target site.
Deep sequencing analysis demonstrated that two out of
the three HtH nucleases displayed significant levels of
targeted mutagenesis (2% and 35% of mutagenesis fre-
quencies, Table 1). For the TtH conformation, all three
nucleases showed activity on their respective target se-
quence, with Indel frequencies ranging from 2 to 9%
(Table 1). However, the level of targeted mutagenesis
generated by these two architectures (HtH and TtH dis-
played respectively 12% and 5% mean Indels frequencies)
was lower than that reported for the classical TtT in two
large scale studies (22% and 16% mean Indel frequen-
cies) [28,29].
We next compared the NHEJ-dependent molecular
events promoted by the nuclease activity of the two dif-
ferent architectures versus the classical TtT. Toward this
goal, we generated 10 TtT TALEN, performed targeted
mutagenesis experiments in 293H cells and recovered
the resulting deep-sequencing dataset (Additional file 1:
Table S6 and S7). We first compared the deletion length
induced by the three different architectures and found
similar patterns (p-value = 0.3852) with a large propor-
tion of deletions smaller than 20 bp (Figure 2B-D), a feature
previously described for the conventional TtT architecture
[30]. However the important error bars obtained for some
deletion sizes indicated a variability of DNA repair outcomes
from one locus to another. Such variability could be due to
several parameters including the RVD composition (DNA
binding affinities) and the presence of micro-homologies in
the targeted locus.
We then compared the position of mutagenic events
within the spacer of each architecture target. Considering
the fact that the optimal distance of cleavage was different
for the two TtT and HtH symmetrical architectures, we
hypothesized that the position of mutagenic events within
the target spacer of TtH asymmetrical architecture would
be eccentric. Interestingly, a statistical analysis of the dele-
tion profiles revealed that its activity led to a significant
shift of the deletion pattern (t-test, p-value = 0.00155 with
respect to the TtT architecture) towards the TALE::FokI
binding site (Figure 2E, Figure 3A and B). Due to their
symmetrical configuration, the TtT and HtH architectures
were expected to cleave right in the middle of their op-
timal target (Figure 1B) and thus, 7 to 8 bp and 12 to
13 bp away from the 3’ end of their respective FokI::
TALE and TALE::FokI binding sites. However, due to
its asymmetrical configuration, the TtH architecture
was rather expected to cleave 2 to 3 bp away from the
middle of its optimal target. The consistency between
our experimental data and theoretical expectations in-
dicated that the position of cleavage catalyzed by the
TtH nuclease is constrained by its FokI::TALE scaffold
component.
Figure 2 In vivo nuclease activity of the three nuclease architectures in mammalian cells. (A) Schematic representation of nuclease-mediated
gene inactivation via the error-prone NHEJ pathway. (B) Size distribution of the deletion events induced at the endogenous locus by the TtH architecture.
Loci presenting at least 20 events were taken into account to generate the figure. Error bars denote s.d. Student t test performed to compare deletion
patterns induced by TtT and TtH architectures showed no statistical difference (p-value = 0.3852). (C) Same as for (A) but for the HtH nuclease
architecture. One locus presenting at least 20 events was used. (D) Same as for (A) but for the TtT nuclease architecture. (E) Representation
of the localization of the deletion center for the three architectures. The Gaussian curves having the same mean and variance of deletion
centers for each of the three TtH, HtH, and TtT architectures are represented. The areas under the curves have been normalized to 1. t-test,
p-value = 0.00155 with respect to the TtT architecture. For the TtT and HtH architectures, due to the odd number of nucleotides present in
their spacer (15 or 25 respectively), we arbitrary chose to place the center of the spacer at 8 or 13 bp, explaining the shift of the deletion
center close to -1. Data from 3 loci (DMD, FUT8 and RAG) were used for the HtH and TtH architectures. Data from 10 loci (APC, MLH, CD52,
NR3C3, LIG4, BBC3, NR3C2, M2K, PPARD, ERBB2) were used for the TtT architectures.
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In this paper, we explored the versatility of the TALE scaf-
fold and exploited it to generate a novel asymmetric FokI-
based TALE nuclease architecture. This architecture called
TtH TALE nuclease consisted of the asymmetrical associ-
ation of TALE::FokI and FokI::TALE scaffolds (Figure 1A),two different engineered TALE DNA binding domains
fused to the N- and C-terminal ends of FokI nuclease do-
main. Its nuclease activity was characterized in yeast to-
ward extrachromosomal surrogate targets as well as in
mammalian cells at different endogenous loci. Our results
showed that this architecture was active in yeast and
Table 1 Activities of the TtH and HtH nuclease architectures at their endogenous cognate targets
Architectures and endogenous loci Total events [%] Total events [nb] Insertion [nb] Deletion [nb] Wt [nb] Reads [nb]
TtH DMD NC_000023.10: 32,364,567-32,364,620 1.8 193 58 141 10538 10731
(16) (48)
ctrl DMD NC_000023.10: 32,364,567-32,364,620 0 0 0 0 7837 7837
TtH RAG1 NC_000011.9: 36,594,622-36,594,675 2.6 59 18 41 2221 2280
(7) (24)
ctrl RAG1 NC_000011.9: 36,594,622-36,594,675 0 0 0 0 5494 5494
TtH FUT8 NW_003613860.1 673,480-673,533 8.7 459 134 330 4817 5276
(60) (80)
ctrl FUT8 NW_003613860.1 673,480-673,533 0.033 2 1 1 6129 6131
HtH DMD NC_000023.10: 32,364,534-32,364,592 0.01 1 1 0 9147 9148
ctrl DMD NC_000023.10: 32,364,534-32,364,592 0.01 1 1 0 9540 9541
HtH RAG1 NC_000011.9: 36,594,571-36,594,629 1.2 10 5 6 861 871
(3) (6)
ctrl RAG1 NC_000011.9: 36,594,571-36,594,629 0.051 2 1 1 3913 3915
HtH FUT8 NW_003613860.1: 673,442-673,500 30.5 1791 1191 613 4088 5879
(64) (159)
ctrl FUT8 NW_003613860.1: 673,442-673,500 0 0 0 0 7223 7223
The number of unique events (considering the size and position) is indicated in brackets. Control (ctrl) indicates a tranfection with an empty vector plasmid.
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tiple endogenous loci in mammalian cells. Importantly,
the TtH architecture only required one DNA strand of a
given locus to efficiently bind and process it. Such novel
configuration thus extends the range of TALE nucleases
applications.
Today, the conventional TALE nuclease architecture
used by most investigators results from the symmetrical
association of two TALE::FokI scaffolds (Figure 1A and
1D). To be active as nuclease entity, this scaffolds need
to bind in a Tail to Tail (TtT) orientation to adjacent
binding sites bearing a T0 at their 5’ ends and located on
the reverse and forward strand of the locus to process.
Although highly efficient, such architecture is unable to
process loci devoided of thymidine residues either on
one or two strands. To overcome such requirement for
T0 and at the same time, to extend the range of TALE-
based applications, two different groups employed ra-
tional design and directed evolution to modify the TALE
N-terminal domain, a region reported to play a key role
in the T0 specificity of TALE [31,32]. In another study,
such requirement for T0 was reported to be overcome
by using a new modular base-per-base binding domains
(M3BD) scaffold from Burkholderia rhizoxinica [33].
Relaxing the T0 specificity of TALE binding domain
might not be the only strategy to extend the range of
TALE-based applications. Alternative approaches, exploit-
ing the versatility of the TALE scaffold, could also be con-
sidered to abrogate the requirement of two T0 located on
adjacent and anti-parallel TALE binding sites while stilldelivering efficient TALE nuclease activity. To develop
such alternative approach, we first ruled out altering the
T0 specificity of the TALE N-terminal domain, consider-
ing that keeping this binding anchor at the 5’ end of each
TALE DNA binding domain would be beneficial for the
specificity and safety of the resulting designer nuclease.
We thus sought to set up a novel dimeric TALE nuclease
architecture that would require two adjacent TALE bind-
ing sites located on only one strand of the locus of inter-
est. Because of the oriented fashion of TALE domain
binding and the requirement for FokI dimerization, such
architecture named TtH, required the asymmetrical asso-
ciation of two different TALE scaffolds, the TALE::FokI
and the FokI::TALE in a Tail to Head orientation
(Figure 1E).
We developed and tested combinations of the FokI::
TALE and TALE::FokI scaffolds and found that the sym-
metrical HtH and TtT architectures as well as the asym-
metrical TtH architecture could efficiently catalyze targeted
DSBs in a yeast-based nuclease assay. Although the differ-
ent architectures displayed similar activity levels, they
showed marked differences regarding the properties of
their targets. Interestingly, the narrower spacer range
cleaved by the two new HtH and TtH architectures
could represent an advantage by reducing the number
of potential off-site targets in a genome of interest. In-
deed, off-site targets are usually determined as sequences
(combinations of left + right, left + left, right + right se-
quences) diverging from the intended target site by a few
base pairs. In addition, to be considered as a potential
Figure 3 Characterization of mutagenic events promoted by the HtH and TtH nuclease architectures in mammalian cells. (A) Alignment
of the WT genomic sequence and predominant deletion events induced by the HtH architecture at two different endogenous loci. FokI::TALE
scaffold binding sites are represented by capital letters. (B) Same as (A) but for the TtH architecture at the three different endogenous loci. The
targeted sequence is colored with respect to the scaffold binding site considered (blue: FokI::TALE, red: TALE::FokI). The position 0 is underlined.
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by a spacer compatible with a nuclease activity. Based on
the results presented in this study (Figure 1D), 25 different
spacers have to be taken in account for the “classical” TtT
architecture. Regarding the HtH and TtH architectures
only 8 or 16 different spacer lengths need to be considered
respectively (Figures 1C and E). These differences resulted
in an approximate 3 and 2 fold higher numbers of poten-
tial off-site targets for the TtT compared to the HtH and
TtH architectures respectively. In addition, we believed
that the global nuclease activity and specificity could still
be improved by optimizing the flexibility and/or rigidity of
the aminoacid linker between the FokI and TALE domain.
Indeed, Mercer and colleagues have recently shown that
fusion of recombinase catalytic domain to alternative
truncations of TALE N-terminal domain (Δ120 or Δ128)
could enhance the efficiency of their chimeric TALE
recombinase system [12].
As the levels of activities obtained in the yeast SSA assay
were fully satisfactory, we evaluated the performance of the
two HtH and TtH architectures in a chromosomal context.
We thus generated three pairs of nucleases for both archi-
tectures following the guidelines (spacer length) obtained
previously in yeast, to target a total of six loci in two mam-
malian cell types (CHO-KI and 293H). The efficiency of
these nucleases to induce DSB events was monitored 3 days
post transfection by measuring Indels generated by NHEJ
at their cleavage sites. We cannot exclude that variation innuclease activity is dependent on multiple parameters and
is thus not exclusively resulting from the difference in
architecture. Indeed, the RVD composition of the nuclease,
the targeted DNA sequence and the presence of micro-
homologies within the targeted loci are likely to influence
several biochemical parameters such as overall DNA
binding, cleavage efficiency and global DNA repair
outcome. Nevertheless, we found that both architec-
tures induced a substantial level of targeted mutagenesis
(Table 1). Additionally, the molecular characterization of
deletion events allowed us to observe that the DSB oc-
curred in the middle of the spacer region for the TtT and
HtH architecture while being shifted toward the TALE::
FokI scaffold binding site of the new TtH architecture.
While TtH architecture does not significantly increase
the number of targetable loci, it could be endowed with
a new technological advantage for the field of gene ther-
apy. Indeed, when considering the human chromosome
1 as a model, and using standard criteria for the array
(15.5 repeats) and spacer (10-16 and 20-25 bp) length
[26], we estimated that the classical TtT architecture could
target about 99.8% of this chromosome. The remaining
0.2% comprised a total of 2945 regions of 68 to 1983 bp
(representing a total of 346422 nucleotides) that were
devoided of any TtT nuclease target. We noted that more
than half of these sequences could be potentially targeted
using the TtH configuration (array of 15.5 repeats and spa-
cer of 17-23 and 26-33 bp, Figure 1E) and that an important
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petitive motives. Expansion of triplets or quadruplets is
commonly linked to several genetic disorders and different
neurological syndromes [34]. Their expansion induces aber-
rant protein expressions and subsequent aggregation, as well
as formation and persistence of RNA:DNA hybrids respon-
sible for genomic instability and inhibition of replication.
Processing such pathogenic sequences represents important
therapeutic potentials to cure their related genetic disease
and, in that matter, the advantages of the new TtH architec-
ture are twofold with respect to conventional TALEN
architecture. First, it could process and thus stimulate
contraction of expanded sequences harboring thymidine
on one unique strand (CAG, GAA, CTG and CCTG).
Second, through the well known ability of FokI to cleave
DNA:RNA hybrids along with the capacity of TALE do-
main to interact with such molecule [35], it could also re-
duce the deleterious downstream effects of DNA:RNA
duplex via their targeted processing. Noteworthy, such ap-
proach could also be used in general to process DNA:
RNA hybrids.
Finally, besides its potential for specific gene therapy
application, the TtH architecture could be beneficial for
the field of genome editing by allowing for more precise
positioning of TALE nuclease without affecting their T0
specificity, one of the hallmark of their DNA specificity.Conclusions
Overall, although a larger dataset would be desirable,
our results demonstrate that the level of genome modi-
fications that can be obtained in mammalian cells with
the new TtH architecture is compatible with most, if
not all, genome editing applications. An additional
benefit of this particular asymmetrical architecture is
the availability of both N- and C-termini that can also
expand the “cargo” possibility of TALE-based nucleases.
We believe that this particular TtH architecture will
further expand the possibilities of the TALE-based
nuclease technology for targeting sequences with biased
nucleotide composition (e.g. highly repetitive motives)
or DNA-RNA hybrids.Methods
TALE arrays
All TALE arrays were obtained from Cellectis Biore-
search (Paris, France). TALEN™ is a trademark owned by
Cellectis Bioresearch. Sequences of TALE-nuclease back-
bones, TALE RVD array composition and/or relevant
targets are presented in the Additional file 1. For experi-
ments in mammalian cell lines, the TALE-based nucle-
ases were expressed under the control of either an EF1a
promoter (HtH and TtH architectures) or a CMV pro-
moter (TtT architecture).Extrachromosomal SSA assay in yeast
TALE-based nuclease containing yeast strain were grid-
ded at high gridding density (∼20 spots/cm2) on nylon
filters placed on solid agar containing YP-glycerol plates,
using a colony gridder (QpixII, Genetix). A second layer,
consisting of reporter-harboring yeast strains, was grid-
ded on the same filter for each target. Membranes were
incubated overnight at 30°C to allow mating. To select
for diploids, filters were then places and incubated for
2 days at 30°C on medium containing glucose (2%) as
the carbon source but lacking leucine (for the TALE nu-
clease left arm), tryptophan (for the target) and supple-
mented with G418 (for the TALE nuclease right arm, if
required). To induce the expression of the TALE-based
nuclease, filters were transferred onto YP-galactose-rich
medium for 24-48 hours at 30°C or 37°C. To monitor
nuclease activity, through the β-galactosidase activity, fil-
ters were finally placed on solid agarose medium con-
taining 0.02% X-Gal in 0.5 M sodium phosphate buffer,
pH 7.0, 0.1% SDS, 6% dimethyl formamide (DMF),
7 mM β-mercaptoethanol, 1% agarose and incubated at
37°C for up to 48 h.
Filters were scanned and each spot was quantified
using the median values of the pixels constituting the
spot. We attribute the arbitrary values 0 and 1 to white
and dark pixels, respectively. β-Galactosidase activity is
directly associated with the efficiency of homologous re-
combination, thus with the cleavage efficiency of the
TALE-based nuclease. Any value >0 is considered as the
consequence of cleavage.
Nuclease transfection in 293H cells
Human 293H cells (Life Technologies) were cultured at
37°C with 5% CO2 in DMEM complete medium supple-
mented with 2 mM L-glutamine, penicillin (100 IU/ml),
streptomycin (100 μg/ml), amphotericin B (Fongizone:
0.25 μg/ml, Life Technologies,) and 10% FBS. Adherent
293H cells were seeded at 1.2 106 cells in 10 cm Petri
dishes one day before transfection. Cell transfection was
performed using the Lipofectamine 2000 reagent accord-
ing to the manufacturer’s instructions (Invitrogen). In
brief, 2.5 μg (for the HtH and TtH architectures) or
12 μg (for the TtT architecture) of each of the two nu-
clease expression vector pairs, and 10 ng of GFP expres-
sion vector (to monitor transfection efficiencies) were
mixed with 0.3 ml of DMEM without FBS (5 μg final
DNA amount). In another tube 25 μL of Lipofectamine
were mixed with 0.3 ml of DMEM without FBS. After
5 minutes incubation, both DNA and Lipofectamine
mixes were combined and incubated for 20 min at RT.
The mixture was transferred to a Petri dish containing
the 293H cells in 9 ml of complete medium and then cul-
tured at 37°C under 5% CO2. Three days post-transfection,
the cells were washed with phosphate-buffered saline
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and the percentage of GFP positive cells was measured by
flow cytometry (Guava EasyCyte) in order to monitor
transfection efficacy.
Nuclease transfection in CHO-KI cells
CHO-K1 cells (ATCC) were cultured at 37°C with 5%
CO2 in F-12 K complete medium (Gibco) supplemented
with 2 mM L-glutamine, penicillin (100 IU/ml), strepto-
mycin (100 μg/ml), amphotericin B (Fongizone: 0.25 μg/ml,
Life Technologies,) and 10% FBS. Cell transfection was per-
formed by electroporation with the Nucleofector Kit T for
CHO-K1 cells (Lonza) according to the manufacturer’s
protocol. Cells (1 x 106 cells) were transfected with 5 μg of
the two nuclease expression vector pairs and 10 ng of GFP
expression vector (to monitor transfection efficiencies)
(10 μg final DNA amount), then plated in a 10 cm dish
in complete medium (F-12 K medium, Gibco) supple-
mented with 2 mM L-glutamine, penicillin (100 IU/ml),
streptomycin (100 μg/ml), Fongizone (0.25 μg/ml) and 10%
FBS. Three days post-transfection, the cells were washed
with phosphate-buffered saline (PBS), trypsinized, resus-
pended in 5 ml complete medium and the percentage of
GFP positive cells was measured by flow cytometry (Guava
EasyCyte) in order to monitor transfection efficacy.
Targeted mutagenesis
Cells were pelleted by centrifugation and genomic DNA
was extracted using DNeasy Blood & Tissue Kit (Qiagen)
according to the manufacturer’s instructions. PCR of the
endogenous locus (370-630 bp final product size) were
performed using the oligonucleotide sequences presented
in the Additional file 1 and purified using the AMPure kit
(Invitrogen). Amplicons were further analyzed by deep se-
quencing using the 454 system (Roche) [36].
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